PE20220383A1 - Glicoproteinas sialiladas - Google Patents

Glicoproteinas sialiladas

Info

Publication number
PE20220383A1
PE20220383A1 PE2021001732A PE2021001732A PE20220383A1 PE 20220383 A1 PE20220383 A1 PE 20220383A1 PE 2021001732 A PE2021001732 A PE 2021001732A PE 2021001732 A PE2021001732 A PE 2021001732A PE 20220383 A1 PE20220383 A1 PE 20220383A1
Authority
PE
Peru
Prior art keywords
shear stress
sialilated
glycoproteins
stable
pharmaceutical
Prior art date
Application number
PE2021001732A
Other languages
English (en)
Inventor
Siddhesh D Patil
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20220383A1 publication Critical patent/PE20220383A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Se describen preparaciones farmaceuticas que contienen inmunoglobulinas hipersialiladas. Las preparaciones son estables al esfuerzo de cizalla. Las composiciones farmaceuticas descritas en la presente descripcion proporcionan composiciones de hsIgG farmaceuticamente aceptables que son estables contra el esfuerzo de cizalla (p. ej., no se forman un numero significativo de particulas subvisibles cuando la formulacion se somete a esfuerzo de cizalla, tal como agitacion, por ejemplo, durante el envio) y, por lo tanto, pueden enviarse y manipularse en forma liquida.
PE2021001732A 2019-04-18 2020-04-17 Glicoproteinas sialiladas PE20220383A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836016P 2019-04-18 2019-04-18
PCT/US2020/028863 WO2020215021A1 (en) 2019-04-18 2020-04-17 Sialylated glycoproteins

Publications (1)

Publication Number Publication Date
PE20220383A1 true PE20220383A1 (es) 2022-03-18

Family

ID=72837963

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001732A PE20220383A1 (es) 2019-04-18 2020-04-17 Glicoproteinas sialiladas

Country Status (20)

Country Link
US (1) US20220211849A1 (es)
EP (1) EP3955962A4 (es)
JP (1) JP2022529168A (es)
KR (1) KR20220002963A (es)
CN (1) CN113795275A (es)
AU (1) AU2020259492A1 (es)
BR (1) BR112021020509A8 (es)
CA (1) CA3137101A1 (es)
CL (1) CL2021002668A1 (es)
CO (1) CO2021013926A2 (es)
CR (1) CR20210521A (es)
EA (1) EA202192860A1 (es)
EC (1) ECSP21078309A (es)
IL (1) IL287306A (es)
JO (1) JOP20210281A1 (es)
MX (1) MX2021012710A (es)
PE (1) PE20220383A1 (es)
SG (1) SG11202110942SA (es)
WO (1) WO2020215021A1 (es)
ZA (1) ZA202109184B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3927729A4 (en) 2019-02-18 2023-10-11 Eli Lilly and Company THERAPEUTIC ANTIBODY FORMULATION
EP4248218A1 (en) 2020-11-20 2023-09-27 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832756A (zh) * 2003-06-09 2006-09-13 约翰·A·麦金太尔 通过氧化还原反应改变血浆蛋白质结合专一性的方法
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
JP2009503105A (ja) * 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
CN102459331B (zh) * 2009-05-27 2015-01-28 巴克斯特国际公司 生产用于皮下使用的高度浓缩的免疫球蛋白制品的方法
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
US20150252108A1 (en) * 2012-09-26 2015-09-10 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
US20160108450A1 (en) * 2013-05-02 2016-04-21 Momenta Pharmaceutcals, Inc. Sialylated glycoproteins
JP6594860B2 (ja) * 2013-05-29 2019-10-23 エフ．ホフマン−ラ ロシュ アーゲー シアル酸付加の定量的調節
AU2018207367B2 (en) * 2017-01-11 2024-02-15 Celltrion Inc. Stable Liquid Formula

Also Published As

Publication number Publication date
EP3955962A4 (en) 2022-12-14
IL287306A (en) 2021-12-01
WO2020215021A1 (en) 2020-10-22
ECSP21078309A (es) 2021-11-30
AU2020259492A1 (en) 2021-11-11
EP3955962A1 (en) 2022-02-23
EA202192860A1 (ru) 2021-12-23
CN113795275A (zh) 2021-12-14
JP2022529168A (ja) 2022-06-17
BR112021020509A2 (pt) 2022-03-15
MX2021012710A (es) 2021-11-12
SG11202110942SA (en) 2021-11-29
ZA202109184B (en) 2023-04-26
CL2021002668A1 (es) 2022-05-27
US20220211849A1 (en) 2022-07-07
CR20210521A (es) 2022-04-01
CA3137101A1 (en) 2020-10-22
JOP20210281A1 (ar) 2023-01-30
CO2021013926A2 (es) 2021-10-29
BR112021020509A8 (pt) 2023-01-10
KR20220002963A (ko) 2022-01-07

Similar Documents

Publication Publication Date Title
ECSP21078309A (es) Glicoproteínas sialiladas
CL2019002828A1 (es) Formulación estable de anticuerpos.
ES2656901T3 (es) Una formulación estabilizada de pemetrexed
BR112018008880A2 (pt) composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7
SG10201806300VA (en) Liquid pharmaceutical composition
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
AR102096A1 (es) Proceso para elaborar acetato de glatiramer
CO2021005915A2 (es) Composiciones estables de semaglutida y usos de las mismas
BR112022001330A2 (pt) Derivados de 3,6-diamino-piridazin-3-ila, composições farmacêuticas contendo-os e seus usos como agentes pró-apoptóticos
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
AR112536A1 (es) Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos
MX2022013566A (es) Anticuerpo.
CO2018012502A2 (es) Formulaciones y métodos para el tratamiento de organismos fotosintéticos y la mejora de las calidades y cantidades de rendimientos con formulaciones de compuestos de glicano
AR118881A1 (es) Composiciones de virus inactivado y formulaciones de vacuna contra el zika
JP2016138094A (ja) 外用組成物
BR112022009784A2 (pt) Composições injetáveis de ácido ursodesoxicólico.
BR112022004674A2 (pt) Ácido canforsulfônico e combinações do mesmo com excipientes catiônicos como agentes de redução de viscosidade em formulações de proteína altamente concentradas
MX2023000348A (es) Composicion que contiene ciclodextrina y busulfan.
BR112021026492A2 (pt) Formulações líquidas, formulação liofilizada, artigos de fabricação e método para preparar uma formulação líquida
CO2021004612A2 (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento
PE20030098A1 (es) Capsulas elasticas blandas y composiciones de las mismas
AR123578A1 (es) Mezclas de polisorbato que tienen distribución de ésteres de ácidos grasos modificados
EA201800229A1 (ru) Способ получения пеметрекседа динатрия 2,5-гидрата и фармацевтическая композиция, содержащая пеметрекседа динатрия 2,5-гидрат
BR112022023738A2 (pt) Formulação líquida